0001493152-18-013540.txt : 20180920
0001493152-18-013540.hdr.sgml : 20180920
20180920160525
ACCESSION NUMBER: 0001493152-18-013540
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180815
FILED AS OF DATE: 20180920
DATE AS OF CHANGE: 20180920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCartney Michael Brian
CENTRAL INDEX KEY: 0001743965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35817
FILM NUMBER: 181079484
MAIL ADDRESS:
STREET 1: C/O CANCER GENETICS, INC.
STREET 2: 201 ROUTE 17 N, 2ND FLOOR
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CANCER GENETICS, INC
CENTRAL INDEX KEY: 0001349929
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 043462475
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 ROUTE 17 NORTH
STREET 2: 2ND FLOOR
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
BUSINESS PHONE: 201.528.9200
MAIL ADDRESS:
STREET 1: 201 ROUTE 17 NORTH
STREET 2: 2ND FLOOR
CITY: RUTHERFORD
STATE: NJ
ZIP: 07070
FORMER COMPANY:
FORMER CONFORMED NAME: CANCER GENETICS INC
DATE OF NAME CHANGE: 20060117
4
1
ownership.xml
X0306
4
2018-08-15
0
0001349929
CANCER GENETICS, INC
CGIX
0001743965
McCartney Michael Brian
C/O CANCER GENETICS, INC. 201 ROUTE 17N
2ND FLOOR
RUTHERFORD
NJ
07070
0
1
0
0
Chief Commercial Officer
Stock Option (right to buy)
1.03
2018-08-15
4
A
0
100000
0
A
2028-08-15
Common Stock
100000
100000
D
The option award was made in accordance with the terms of the Amended and Restated Cancer Genetics, Inc. 2011 Equity Incentive Plan (the "2011 Plan"). The shares underlying the options shall become vested and exercisable with respect to twenty percent (20%) of the shares on the one-year anniversary of the date of grant and with respect to the remaining eighty percent (80%) of the shares in equal monthly installments on the 15th day of each of the forty-eight (48) calendar months thereafter, provided that the optionee remains a services provider to the Company through each applicable vesting period. The exercise price is the closing price of a share of Common Stock as of the date of grant on the NASDAQ Capital Market in accordance with the terms of the 2011 Plan.
/s/ Michael McCartney by John A. Roberts, Attorney-in-Fact
2018-09-20